Survival prolongation in HIV-associated progressive multifocal leukoencephalopathy treated with alpha-Interferon: an observational study

Reference

• Albrecht H., Hoffman C., Degen O. et al. Highly active antiretroviral (HAART) significantly improved the prognosis of patients (pts) with HIV-associated progressive multifocal leukoencephalopathy (abstract). 1997, 37th ICCAC San Francisco, 1997
   Google Scholar
• Berger J. R., Concha M. Progressive multifocal leukoencephalopathy: the evolution of a disease once considered rare. Neurovirol 1995; 1: 5–18
   PubMed Web of Science ®Google Scholar
• Berger J. R., Kaszovitz B., Post J. D., Dickinson G. Progressive multifocal leukoencephalopathy associated with Human Immunodeficiency Virus Infection. Ann Intern Med 1987; 107: 78–87
   PubMed Web of Science ®Google Scholar
• Berger J. R., Levy R. M. AIDS and the nervous system. Lippencott-Raven, Philadelphia 1997
   Google Scholar
• Berger J. R., Mucke L. Prolonged survival and partial recovery in AIDS-associated Progressive Multifocal Leukoencephalopathy. Neurology 1988; 38: 1060–1065
   PubMed Web of Science ®Google Scholar
• Berger J. R., Pall L., Mcarthur J. C., Colin H., Cimoch P., Evans B. et al. A pilot study of recombinant alpha 2A interferon in the treatment of AIDS-related progressive multifocal leukoencephalopathy (abstract). Neurology 1992; 42: 257, Suppl 3
   Google Scholar
• Brooks B. R., Walker D. L. Progressive multifocal leukoencephalopathy. Neurol Clin 1984; 2: 229–313
   Google Scholar
• Colosimo C., Legon P., Martelli M., Tumminelli F., Mandelli F. Alpha-interferon therapy in a case of probable Progressive Multifocal Leukoencephalopathy. Acta Neurologica Belgica 1992; 92(1)24–29
   Google Scholar
• Counihan T. J., Venna N., Craven D., Savin T. D. Alpha interferon in AIDS-related progressive multifocal leukoencephalopathy. Neuro AIDS 1996; 1: 79
   PubMedGoogle Scholar
• Dianzani F., Antonelli G., Amicucci P., Cefano A., Pintus C. Low incidence of neutralizing antibody formation to interferon-alpha 2b in human recipients. J Interferon Res 1989; 9: S33–S36, Suppl 1
   PubMedGoogle Scholar
• Elliot B. C., Aromin I., Flanigan T. P., Mileno M. Leukoencephalopathy with combined antiretroviral therapy (abstract). Internatinal Conf AIDS 1996; 11(2)222
   Google Scholar
• Gall S. A. Human papillomavirus infection and therapy with interferon. Am J of Obs and Gyn 1995; 172(4 pt 2)1354–1359
   Google Scholar
• Gillespie S. M., Chang Y., Lemp G., Arthur R., Buchbinder S., Steimle A. et al. Progressive multifocal leukoencephalopathy in persons infected with Human Immunodefiency Virus, San Francisco, 1981–1989. Ann of Neurol 1991; 30(4)597–604
   Web of Science ®Google Scholar
• Glesby M. J., Hoover D. R. Survivor Treatment Selection Bias in Observational Studies: Examples from the AIDS Literature. Ann Intern Med 1996; 124: 999–1005
   PubMed Web of Science ®Google Scholar
• Guttennan J. U. Cytokine therapeutics: lessons from interferon alpha. Proc Nat Acad Sci 1994; 91(4)1198–1205
   Google Scholar
• Hall C., Timpone J., Dafni I., Antonijevic Z., et al. ARA-C treatment of PML in AIDS patients (abstract). 4th International Conference on Retroviruses and Opportunistic Infections. Washington DCUSA 1997
   Google Scholar
• Henry K., Worley J., Sullivan C et al. Documented improvement in late stage manifestations of AIDS after starting ritonavir in combination with two reverse transcriptase inhibitors (abstract). Opportun Infect Jan 1997; 22–26: 130
   Google Scholar
• Houff S. A., Major E. O., Katz D., Kufta C., Sever J., Pittaluga S., Roberts J., Bitt J., Saini N., Lux W. Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy. N Engl J Med 1988; 318: 301–305
   PubMed Web of Science ®Google Scholar
• Kurschel E., Metz-Kurschel U., Niederle N., Aulbert E. Investigations on the subclinical and clinical nephrotoxicity of interferon alpha-2B in patients with myeloproliferative syndromes. Renal Failure 1991; 13(2–3?)87–93
   Google Scholar
• Lane H. C., Davey B., Kovacs J. A., Feinberg J., Metcalf J. A., Herpin B. et al. Interferon-alpha in patients with asymptomatic Human Immunodeficiency Virus (HIV) infection. Ann Intern Med 1990; 112: 805–811
   PubMed Web of Science ®Google Scholar
• Major E. O., Amemiya K., Tornatore C. S., Houff S. A., Berger J. R. Pathogenesis and Molecular Biology of Progressive Multifocal Leukoencephalopathy, the JC Virus-Induced Demyelinating Disease of the Human Brain. Clin Microbio Rev 1992; 1: 49–73
   Google Scholar
• Major E. O., Ault G. S. Progressive multifocal leukoencephalopathy: clinical and laboratory observations on a viral induced demyelinating disease in the immunodeficient patient. Current Opinion in Neurology 1995; 8: 184–190
   Google Scholar
• Portegies P., Algra P. R., Hollak C.E.M, Prins J. M., Reiss P., Valk J. et al. Response to cytarabine in Progressive Multifocal Leukoencephalopathy in AIDS. Lancet 1991; 337: 680–681
   PubMed Web of Science ®Google Scholar
• Radwanski E., Perentesis G., Jocobs S., Oden E., Affrime M., Symchowicz S. et al. Pharmacokinetics of interferon alpha-2b in healthy volunteers. Clin Pharmacol 1987; 27: 432–435
   Google Scholar
• Ronnblom L. E., Aim G. V., Oberg K. E. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 1991; 115(3)178–183
   Google Scholar
• Shah K., Nathanson N. Human exposure to SV40: Review and comment. Am J Epidem 1976; 103(1)1–12
   Google Scholar
• Smith R. A., Norris F., Palmer D. et al. Distribution of alpha interferon in serum and cerebrospinal fluid after systemic administration. Clin Pharmacol Ther 1985; 37: 85–88
   PubMed Web of Science ®Google Scholar
• Spiegel R. J., Jacobs S. L., Treuhaft M. W. Anti-interferon antibodies to interferon-alpha 2b: results of comparative assays and clinical perspective. J Interferon Res 1989; 9: S17–S24, Suppl 1
   PubMedGoogle Scholar
• Steiger M. J., Tarnesby G., Gabe S., Mclaughlin J., Schapire A. H. Successful outcome of Progressive Multifocal Leukoencephalopathy with cytarabine and interferon. Ann Neurol 1993; 33(4)407–411
   Google Scholar
• Trapp B. D., Small J. A., Pulley B. A., Khoury G., Scangos G. A. Dysmyelination in transgenic mice containing JC virus early region. Ann Neurol 1988; 23: 38–48
   Google Scholar
• Vial R., Descotes J. Clinical toxicity of the interferons. Drug Saf 1994; 10(2)115–150
   PubMed Web of Science ®Google Scholar
• Walker D. L., Padgett B. L. The epidemiology of human polyomaviruses. Polyomaviruses and Human Neurological Diseases. Alan R. Liss, Inc., New York 1993; 99–106
   Google Scholar
• Zurhein G., Chou S. M. Particles resembling papovaviruses in human cerebral demyelinating disease. Science 1965; 148: 1477–1479
   PubMed Web of Science ®Google Scholar